Lift of Stay Disallowed by District Court Post-SAS in View of PTAB’s Final Written Decision Lacking Non-Instituted Claims

Jun 18, 2018

Reading Time : 2 min

On July 29, 2015, DermaFocus LLC—a non-practicing entity—filed suit against Ulthera, Inc. in the District of Delaware alleging that the Ulthera infringed U.S. Patent No. 6,113,559 (the “’559 patent”) relating to a method and apparatus for therapeutic treatment of skin with ultrasound. Just shy of one year after DermaFocus’s complaint (on July 19, 2016), Ulthera filed an IPR challenging all claims of the ’559 patent. On November 11, 2016 the parties agreed to stay the district court litigation until the PTAB denied institution or issued a final written decision. Ultimately, the PTAB instituted IPRs on 16 of 18 claims and, on January 19, 2018, issued a final written decision rejecting all of Ulthera’s validity challenges. Consequently, DermaFocus moved to lift the stay.

Courts typically consider three factors when determining whether to stay, or lift a stay, in district court: (1) whether the stay will simplify the issues for trial; (2) the status of the litigation; and (3) whether the nonmoving party will be prejudiced—based on timing, delay, and the relationship of the parties. DermaFocus’s arguments to lift the stay centered on the more than two-year delay in litigation and the fact that the stay’s purpose had been fulfilled following the PTAB’s final written decision finding that all 16 instituted claims were patentable. Ulthera opposed the motion to lift the stay and instead sought a continuation based on its appeal to the Federal Circuit.

Although the aforementioned three factors normally govern motions to stay, Magistrate Judge Fallon determined that the SAS Institute decision mandated a different outcome. In SAS Institute, the Supreme Court ruled against the PTAB’s practice of partial institutions and held that the PTAB must issue final written decisions “with respect to patentability of any patent claim challenged” and that, in this context, “‘any’ means ‘every.’”

In the parallel IPR proceeding, the PTAB had instituted IPR on only 16 of the patent’s 18 claims. Accordingly, following the Supreme Court’s decision, Ulthera had filed a motion with the Federal Circuit requesting remand of the appeal to the PTAB for issuance of a final decision regarding patentability of the two claims not instituted. The Federal Circuit granted Ulthera’s remand motion and stated that the PTAB had “to resolve the patentability of all challenged claims in the pending IPR proceeding.”

As such, Magistrate Judge Fallon ruled that the parties’ stay agreement had not been fulfilled—specifically, the stipulation that the stay would be lifted “pending resolution by the PTAB of the patentability of all challenged claims in the pending IPR.” The motion to lift the stay was, therefore, denied because the conditions for originally implementing the stay still existed:  the PTAB had not finished considering all challenged claims in light of the SAS Institute decision.

DermaFocus LLC v. Ulthera, Inc., 1-15-cv-00654 (D. Del. June 7, 2018) (Fallon, MJ) (order denying motion to lift stay)

Share This Insight

Previous Entries

IP Newsflash

June 6, 2025

In a precedential opinion, the Federal Circuit definitively held that the Patent Trial and Appeal Board has jurisdiction over IPRs that concern expired patents.

...

Read More

IP Newsflash

June 6, 2025

In a patent infringement litigation in the U.S. District Court for the Eastern District of Texas, Judge Rodney Gilstrap denied a joint motion to stay the litigation pending resolution of inter partes review when it was uncertain that all defendants would be bound by the statutory estoppel provision of 35 U.S.C. § 315(e).

...

Read More

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged claim construction issues or the number, length or scope differences of the challenged claims.

...

Read More

IP Newsflash

May 9, 2025

The USPTO Director vacated the board’s decision to institute inter partes review based on an erroneous application of the Fintiv factors. Specifically, the Director found that the board placed too much emphasis on Petitioner’s Sotera stipulation, and not enough emphasis on the investment in the parallel litigation. Weighing the factors as a whole, the Director determined that institution should be denied.

...

Read More

IP Newsflash

May 9, 2025

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.